116 related articles for article (PubMed ID: 35288662)
21. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
[TBL] [Abstract][Full Text] [Related]
24. MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer.
Ross I; Womble P; Ye J; Linsell S; Montie JE; Miller DC; Cher ML
J Urol; 2015 Apr; 193(4):1159-62. PubMed ID: 25444985
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer risk assessment tools in an unscreened population.
Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
[TBL] [Abstract][Full Text] [Related]
26. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
27. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
28. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
Freedland SJ; Howard LE; Hanyok BT; Kadiyala VK; Kuang JY; Whitney CA; Wilks FR; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Aronson WJ; Moreira DM
BJU Int; 2016 Oct; 118(4):570-7. PubMed ID: 26762961
[TBL] [Abstract][Full Text] [Related]
29. Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification.
Draulans C; Everaerts W; Isebaert S; Gevaert T; Oyen R; Joniau S; Lerut E; De Wever L; Weynand B; Vanhoutte E; De Meerleer G; Haustermans K
Urology; 2019 Aug; 130():113-119. PubMed ID: 31051166
[TBL] [Abstract][Full Text] [Related]
30. External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy.
Dell'Oglio P; Abdollah F; Suardi N; Gallina A; Cucchiara V; Vizziello D; Zaffuto E; Cantiello F; Damiano R; Shariat S; Montorsi F; Briganti A
J Endourol; 2014 Apr; 28(4):416-23. PubMed ID: 24188052
[TBL] [Abstract][Full Text] [Related]
31. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
32. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
33. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
[TBL] [Abstract][Full Text] [Related]
34. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators.
Van Calster B; Wynants L; Verbeek JFM; Verbakel JY; Christodoulou E; Vickers AJ; Roobol MJ; Steyerberg EW
Eur Urol; 2018 Dec; 74(6):796-804. PubMed ID: 30241973
[TBL] [Abstract][Full Text] [Related]
35. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients.
McArthur C; McLaughlin G; Meddings RN
Br J Radiol; 2012 Apr; 85(1012):390-4. PubMed ID: 21304009
[TBL] [Abstract][Full Text] [Related]
36. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
37. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
[TBL] [Abstract][Full Text] [Related]
38. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
39. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
40. Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy.
Abdollah F; Sun M; Briganti A; Thuret R; Schmitges J; Gallina A; Suardi N; Capitanio U; Salonia A; Shariat SF; Perrotte P; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2011 Dec; 108(11):1769-75. PubMed ID: 21507189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
